Erschienen in:
12.11.2019 | Colorectal Cancer
Comprehensive Comparative Analysis of Prognostic Value of Systemic Inflammatory Biomarkers for Patients with Stage II/III Colon Cancer
verfasst von:
Shinsuke Suzuki, MD, PhD, Takashi Akiyoshi, MD, PhD, Koji Oba, PhD, Fuhito Otsuka, MPH, Tetsuro Tominaga, MD, PhD, Toshiya Nagasaki, MD, PhD, Yosuke Fukunaga, MD, PhD, Masashi Ueno, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Abstract
Background
Among numerous systemic inflammatory biomarkers, it remains unclear which is the most prognostic for patients with stage II/III colon cancer. We aimed to compare the prognostic significance of systemic inflammatory biomarkers among patients with stage II/III colon cancer.
Methods
We included 1303 patients with stage II/III colon cancer who underwent potentially curative resection from July 2004 to December 2013. Sixteen systemic inflammatory biomarkers—derived from combinations of neutrophils, lymphocytes, monocytes, platelets, C-reactive protein (CRP), and albumin—were compared to identify the biomarker most associated with overall survival (OS) and disease-free survival (DFS) using receiver operating characteristic (ROC) curve analysis.
Results
Nine inflammatory biomarkers were predictive for OS, among which lymphocyte-to-CRP ratio (LCR), CRP-to-albumin ratio (CAR), neutrophil × CRP, monocyte × CRP, and platelet × CRP were also predictive for DFS. Among these five inflammatory biomarkers, the area under the curve (AUC) value was highest (0.630) for LCR, being significantly higher than that for neutrophil × CRP (P = 0.010), monocyte × CRP (P = 0.007), or platelet × CRP (P = 0.010) for OS. When the prognostic impact of LCR and CAR were analyzed by multivariate analysis, only LCR was an independent predictor of both OS [hazard ratio (HR), 1.77; 95% confidence interval (CI), 1.23–2.60; P = 0.002] and DFS (HR, 1.29; 95% CI, 1.00–1.66; P = 0.048).
Conclusions
LCR may be the most useful predictive factor for OS and DFS in patients with stage II or III colon cancer.